Chemed (CHE) Financials

$550.58 +3.80 (+0.69%)

As of 12:26 PM Eastern

Annual Income Statements for Chemed

This table shows Chemed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	110	109	98	206	220	319	269	250	273	302
Consolidated Net Income / (Loss)	110	109	98	206	220	319	269	250	273	302
Net Income / (Loss) Continuing Operations	110	109	98	206	220	319	269	250	273	302
Total Pre-Tax Income	180	177	117	240	262	396	350	330	350	399
Total Operating Income	184	179	113	244	257	390	343	343	341	366
Total Gross Profit	456	461	516	555	617	701	770	765	799	854
Total Revenue	1,543	1,577	1,667	1,783	1,939	2,080	2,139	2,135	2,264	2,431
Operating Revenue	1,543	1,577	1,667	1,783	1,939	2,080	2,139	2,135	2,264	2,431
Total Cost of Revenue	1,088	1,115	1,151	1,228	1,321	1,378	1,369	1,370	1,466	1,577
Operating Cost of Revenue	1,088	1,115	1,151	1,228	1,321	1,378	1,369	1,370	1,466	1,577
Total Operating Expenses	271	283	403	311	360	312	427	422	458	488
Selling, General & Admin Expense	238	248	277	271	306	330	367	359	395	424
Depreciation Expense	32	34	35	38	41	47	49	49	51	53
Amortization Expense	1.13	0.36	0.14	0.40	4.34	9.99	10	10	10	10
Other Operating Expenses / (Income)	-	-	91	1.30	9.13	-75	0.99	3.69	2.26	0.45
Total Other Income / (Expense), net	-4.33	-1.70	3.88	-4.03	4.23	6.31	7.28	-14	9.80	33
Interest Expense	3.65	3.72	4.27	4.99	4.54	2.36	1.87	4.58	3.11	1.78
Other Income / (Expense), net	-0.69	2.02	8.15	0.96	8.76	8.67	9.14	-9.23	13	35
Income Tax Expense	70	68	19	34	42	77	82	80	78	97
Basic Earnings per Share	$6.54	$6.64	$6.11	$12.80	$13.77	$20.02	$17.14	$16.72	$18.11	$20.10
Weighted Average Basic Shares Outstanding	16.87M	16.38M	16.06M	16.06M	15.97M	15.96M	15.67M	14.93M	15.05M	15.02M
Diluted Earnings per Share	$6.33	$6.48	$5.86	$12.23	$13.31	$19.48	$16.85	$16.53	$17.93	$19.89
Weighted Average Diluted Shares Outstanding	17.42M	16.79M	16.74M	16.80M	16.53M	16.40M	15.94M	15.10M	15.20M	15.19M
Weighted Average Basic & Diluted Shares Outstanding	16.90M	16.40M	83.20M	144.70M	16.06M	16.03M	14.99M	14.95M	15.12M	14.64M
Cash Dividends to Common per Share	$0.92	$1.00	$1.08	$1.16	$1.24	$1.32	$1.40	$1.48	$1.56	$1.80

This table shows Chemed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	57	62	54	53	75	90	65	71	76	90
Consolidated Net Income / (Loss)	57	62	54	53	75	90	65	71	76	90
Net Income / (Loss) Continuing Operations	57	62	54	53	75	90	65	71	76	90
Total Pre-Tax Income	76	82	71	70	93	116	84	94	101	120
Total Operating Income	81	81	73	70	87	111	72	88	92	114
Total Gross Profit	180	197	189	180	202	228	204	206	210	234
Total Revenue	526	547	560	554	565	586	589	596	606	640
Operating Revenue	526	547	560	554	565	586	589	596	606	640
Total Cost of Revenue	347	350	371	374	362	358	385	390	396	406
Operating Cost of Revenue	347	350	371	374	362	358	385	390	396	406
Total Operating Expenses	99	116	117	110	115	116	132	118	118	120
Selling, General & Admin Expense	84	97	100	95	100	100	116	102	102	104
Depreciation Expense	12	12	12	13	13	13	13	13	13	13
Amortization Expense	2.52	2.51	2.51	2.51	2.52	2.52	2.52	2.55	2.55	2.57
Other Operating Expenses / (Income)	0.02	4.22	1.74	-0.02	0.34	0.20	0.09	0.04	0.16	0.16
Total Other Income / (Expense), net	-4.39	1.07	-1.65	0.84	6.42	4.20	12	5.70	8.87	6.25
Interest Expense	1.27	1.60	1.55	0.77	0.44	0.34	0.43	0.43	0.43	0.50
Other Income / (Expense), net	-3.12	2.67	-0.10	1.61	6.86	4.54	13	6.13	9.30	6.74
Income Tax Expense	20	20	17	17	18	26	19	23	25	30
Basic Earnings per Share	$3.82	$4.17	$3.62	$3.54	$4.97	$5.98	$4.30	$4.70	$5.04	$6.06
Weighted Average Basic Shares Outstanding	14.89M	14.93M	14.97M	15.06M	15.08M	15.05M	15.12M	15.10M	15.03M	15.02M
Diluted Earnings per Share	$3.78	$4.13	$3.58	$3.51	$4.93	$5.91	$4.24	$4.65	$5.00	$6.00
Weighted Average Diluted Shares Outstanding	15.04M	15.10M	15.11M	15.22M	15.20M	15.20M	15.34M	15.25M	15.17M	15.19M
Weighted Average Basic & Diluted Shares Outstanding	14.87M	14.95M	15.02M	15.08M	15.06M	15.12M	15.14M	15.05M	14.98M	14.64M

This table details how cash moves in and out of Chemed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	0.60	0.58	-4.19	-6.29	1.33	157	-130	41	190	-86
Net Cash From Operating Activities	172	135	162	287	301	489	309	310	330	417
Net Cash From Continuing Operating Activities	172	135	162	287	301	489	309	310	330	417
Net Income / (Loss) Continuing Operations	110	109	98	206	220	319	269	250	273	302
Consolidated Net Income / (Loss)	110	109	98	206	220	319	269	250	273	302
Depreciation Expense	33	35	36	39	45	57	59	59	61	63
Amortization Expense	2.63	2.37	1.75	0.89	0.31	0.31	0.31	0.34	0.58	0.32
Non-Cash Adjustments To Reconcile Net Income	13	21	38	19	30	31	22	38	43	46
Changes in Operating Assets and Liabilities, net	12	-31	-11	23	6.21	82	-41	-37	-46	5.77
Net Cash From Investing Activities	-50	-40	-68	-105	-191	-62	-58	-59	-61	-144
Net Cash From Continuing Investing Activities	-50	-40	-68	-105	-191	-62	-58	-59	-61	-144
Purchase of Property, Plant & Equipment	-44	-40	-64	-53	-53	-59	-59	-57	-57	-50
Acquisitions	-6.61	-	-4.73	-53	-138	-3.60	0.00	-3.53	-3.99	-97
Sale of Property, Plant & Equipment	-	-	-	-	-	1.69	0.90	2.33	0.64	3.32
Other Investing Activities, net	0.43	-0.09	1.42	0.82	0.27	-0.82	0.01	-0.88	-0.43	-0.30
Net Cash From Financing Activities	-121	-95	-99	-188	-109	-271	-381	-209	-80	-359
Net Cash From Continuing Financing Activities	-121	-95	-99	-188	-109	-271	-381	-209	-80	-359
Repayment of Debt	-161	-110	-220	-484	-482	-265	-25	-311	-98	-2.02
Repurchase of Common Equity	-75	-111	-95	-159	-93	-176	-576	-115	-68	-361
Payment of Dividends	-16	-16	-17	-19	-20	-21	-22	-22	-24	-27
Issuance of Debt	103	127	213	470	483	175	210	221	0.49	0.00
Other Financing Activities, net	28	15	20	3.33	1.98	15	33	17	108	31

This table details how cash moves in and out of Chemed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-1.86	66	-16	102	13	91	49	-90	16	-60
Net Cash From Operating Activities	52	100	60	132	29	109	85	78	91	165
Net Cash From Continuing Operating Activities	52	100	60	132	29	109	85	78	91	165
Net Income / (Loss) Continuing Operations	57	62	54	53	75	90	65	71	76	90
Consolidated Net Income / (Loss)	57	62	54	53	75	90	65	71	76	90
Depreciation Expense	15	15	15	15	15	16	16	16	16	16
Amortization Expense	0.09	0.10	0.10	0.33	0.08	0.08	0.08	0.08	0.08	0.08
Non-Cash Adjustments To Reconcile Net Income	6.13	12	11	13	8.94	10	18	8.00	9.12	11
Changes in Operating Assets and Liabilities, net	-26	11	-19	50	-70	-7.45	-14	-17	-10	48
Net Cash From Investing Activities	-14	-19	-17	-17	-15	-12	-19	-93	-19	-13
Net Cash From Continuing Investing Activities	-14	-19	-17	-17	-15	-12	-19	-93	-19	-13
Purchase of Property, Plant & Equipment	-13	-18	-17	-16	-12	-12	-12	-11	-14	-13
Sale of Property, Plant & Equipment	0.28	0.29	0.15	0.21	0.15	0.13	0.09	2.83	0.14	0.26
Other Investing Activities, net	-0.71	-0.04	-0.14	-0.03	-0.24	-0.03	-0.01	-0.26	-0.02	-0.01
Net Cash From Financing Activities	-40	-14	-60	-14	-0.26	-6.09	-16	-74	-56	-212
Net Cash From Continuing Financing Activities	-40	-14	-60	-14	-0.26	-6.09	-16	-74	-56	-212
Repayment of Debt	-37	-8.65	-76	-21	-	-	0.00	-	-	-2.02
Repurchase of Common Equity	-24	-13	0.00	-13	-14	-40	-38	-56	-58	-209
Payment of Dividends	-5.67	-5.63	-5.69	-5.73	-6.03	-6.06	-6.05	-6.06	-7.49	-7.50
Issuance of Debt	20	5.58	-0.13	0.63	-0.54	0.53	-0.66	-0.13	0.41	0.39
Other Financing Activities, net	7.70	7.31	23	26	21	39	29	-13	8.45	5.98

This table presents Chemed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	852	880	920	976	1,268	1,435	1,343	1,442	1,668	1,669
Total Current Assets	151	170	176	160	191	329	230	273	501	395
Cash & Equivalents	15	15	11	4.83	6.16	163	33	74	264	178
Accounts Receivable	106	132	114	120	144	127	137	139	182	171
Inventories, net	6.31	5.76	5.33	5.71	7.46	7.10	10	10	12	8.19
Prepaid Expenses	13	13	16	19	23	26	33	30	30	26
Current Deferred & Refundable Income Taxes	11	3.71	30	11	10	6.60	17	19	13	11
Plant, Property, & Equipment, net	117	121	143	162	176	188	194	200	204	201
Total Noncurrent Assets	584	589	601	654	902	918	919	970	963	1,073
Noncurrent Note & Lease Receivables	-	-	-	-	112	123	125	136	126	127
Goodwill	472	472	477	511	577	579	579	581	585	667
Intangible Assets	55	55	55	68	126	118	108	100	90	92
Employee Benefit Assets	49	54	62	66	77	89	99	93	106	131
Other Noncurrent Operating Assets	7.23	7.04	7.13	9.21	9.05	8.76	8.14	60	56	56
Total Liabilities & Shareholders' Equity	852	880	920	976	1,268	1,435	1,343	1,442	1,668	1,669
Total Liabilities	339	356	380	384	542	534	719	643	560	550
Total Current Liabilities	171	172	194	192	262	299	302	297	312	286
Accounts Payable	44	40	48	50	51	54	73	42	64	44
Accrued Expenses	44	48	47	46	50	55	56	59	59	57
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	0.13	9.46	0.04	0.00	6.86	7.59
Current Employee Benefit Liabilities	53	54	63	63	71	91	96	87	88	92
Other Current Liabilities	23	22	25	32	90	89	78	104	94	85
Total Noncurrent Liabilities	168	184	186	193	279	235	417	346	248	264
Noncurrent Deferred & Payable Income Tax Liabilities	21	14	17	22	19	21	23	39	30	26
Noncurrent Employee Benefit Liabilities	49	54	62	65	76	88	99	92	104	126
Other Noncurrent Operating Liabilities	13	16	17	17	95	125	110	123	114	112
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	513	524	540	591	727	901	623	799	1,108	1,119
Total Preferred & Common Equity	513	524	540	591	727	901	623	799	1,108	1,119
Total Common Equity	513	524	540	591	727	901	623	799	1,108	1,119
Common Stock	637	674	731	810	896	998	1,081	1,187	1,378	1,522
Retained Earnings	866	958	1,039	1,226	1,426	1,724	1,970	2,198	2,447	2,722
Treasury Stock	-992	-1,111	-1,231	-1,446	-1,598	-1,823	-2,430	-2,588	-2,720	-3,127
Other Equity Adjustments	2.40	2.51	2.20	2.34	2.31	2.34	2.20	2.25	2.08	2.22

This table presents Chemed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,356	1,431	1,505	1,562	1,728	1,735	1,769
Total Current Assets	199	262	337	395	540	465	490
Cash & Equivalents	7.78	58	160	173	313	223	238
Accounts Receivable	122	154	120	168	177	185	196
Inventories, net	10	11	12	13	11	11	9.90
Prepaid Expenses	31	29	29	30	28	29	31
Current Deferred & Refundable Income Taxes	28	11	17	11	9.79	17	14
Plant, Property, & Equipment, net	194	204	208	205	203	202	201
Total Noncurrent Assets	964	965	960	962	985	1,068	1,078
Noncurrent Note & Lease Receivables	131	131	127	123	132	132	134
Goodwill	580	581	582	585	592	662	667
Intangible Assets	102	97	95	93	88	97	95
Employee Benefit Assets	90	97	100	104	118	121	127
Other Noncurrent Operating Assets	60	58	57	57	56	56	56
Total Liabilities & Shareholders' Equity	1,356	1,431	1,505	1,562	1,728	1,735	1,769
Total Liabilities	635	551	553	543	544	528	534
Total Current Liabilities	298	283	302	297	282	262	265
Accounts Payable	77	40	41	57	56	43	45
Accrued Expenses	57	63	57	61	62	60	60
Current Deferred & Payable Income Tax Liabilities	0.00	11	-	5.14	27	0.00	3.39
Current Employee Benefit Liabilities	67	50	74	75	50	78	73
Other Current Liabilities	92	114	130	100	87	80	83
Total Noncurrent Liabilities	337	268	251	246	262	266	269
Noncurrent Deferred & Payable Income Tax Liabilities	34	35	37	30	25	28	28
Noncurrent Employee Benefit Liabilities	90	97	99	103	118	120	122
Other Noncurrent Operating Liabilities	117	119	115	112	120	118	119
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	721	880	952	1,019	1,183	1,207	1,236
Total Preferred & Common Equity	721	880	952	1,019	1,183	1,207	1,236
Total Common Equity	721	880	952	1,019	1,183	1,207	1,236
Common Stock	1,137	1,223	1,277	1,291	1,436	1,453	1,500
Retained Earnings	2,141	2,246	2,294	2,363	2,506	2,571	2,639
Treasury Stock	-2,559	-2,592	-2,622	-2,637	-2,761	-2,819	-2,905
Other Equity Adjustments	2.31	2.28	2.32	2.05	2.12	2.15	2.21

This table displays calculated financial ratios and metrics derived from Chemed's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.98%	2.17%	5.70%	6.96%	8.75%	7.27%	2.87%	-0.20%	6.06%	7.37%
EBITDA Growth	5.60%	-0.96%	-27.19%	79.33%	9.61%	46.07%	-9.60%	-4.32%	5.37%	11.98%
EBIT Growth	7.51%	-1.63%	-32.96%	101.83%	8.81%	49.67%	-11.59%	-5.09%	5.75%	13.51%
NOPAT Growth	9.88%	-2.78%	-13.54%	120.19%	3.52%	45.30%	-16.35%	-1.10%	1.85%	4.60%
Net Income Growth	11.03%	-1.39%	-9.72%	109.36%	7.00%	45.26%	-15.94%	-7.05%	9.17%	10.82%
EPS Growth	13.64%	2.37%	-9.57%	108.70%	8.83%	46.36%	-13.50%	-1.90%	8.47%	10.93%
Operating Cash Flow Growth	55.51%	-21.05%	20.02%	76.71%	4.91%	62.42%	-36.93%	0.42%	6.59%	26.40%
Free Cash Flow Firm Growth	63.23%	-23.97%	0.00%	99.62%	-50.15%	373.29%	-41.47%	-5.64%	13.91%	-25.80%
Invested Capital Growth	0.86%	4.71%	2.09%	7.18%	19.94%	-8.87%	4.99%	6.02%	2.66%	11.46%
Revenue Q/Q Growth	1.26%	0.31%	1.52%	1.66%	3.46%	0.53%	0.36%	0.27%	1.76%	2.28%
EBITDA Q/Q Growth	0.11%	1.46%	4.01%	1.99%	7.12%	16.87%	-10.74%	-3.05%	8.60%	1.08%
EBIT Q/Q Growth	-0.30%	1.96%	5.24%	1.97%	6.71%	19.67%	-12.33%	-3.65%	9.93%	1.18%
NOPAT Q/Q Growth	-0.14%	2.43%	26.89%	2.51%	2.65%	17.98%	-11.94%	-5.40%	10.63%	-0.37%
Net Income Q/Q Growth	0.12%	2.12%	29.50%	-0.11%	5.39%	17.76%	-12.72%	-4.77%	11.42%	0.09%
EPS Q/Q Growth	0.48%	3.18%	30.51%	-0.49%	5.80%	18.06%	-11.41%	-3.78%	11.02%	0.45%
Operating Cash Flow Q/Q Growth	-0.50%	-27.51%	-17.94%	42.07%	2.40%	4.99%	-7.02%	13.40%	2.60%	15.60%
Free Cash Flow Firm Q/Q Growth	-3.90%	-31.01%	-25.44%	42.97%	69.43%	4.08%	-4.30%	0.92%	16.95%	42.12%
Invested Capital Q/Q Growth	0.26%	7.11%	16.46%	7.14%	2.16%	7.24%	3.25%	0.93%	-0.26%	-5.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	29.53%	29.26%	30.97%	31.13%	31.85%	33.73%	35.98%	35.84%	35.28%	35.14%
EBITDA Margin	14.25%	13.81%	9.51%	15.95%	16.08%	21.89%	19.24%	18.44%	18.32%	19.11%
Operating Margin	11.95%	11.34%	6.78%	13.67%	13.28%	18.74%	16.04%	16.09%	15.04%	15.07%
EBIT Margin	11.91%	11.46%	7.27%	13.72%	13.73%	19.16%	16.46%	15.66%	15.61%	16.50%
Profit (Net Income) Margin	7.14%	6.90%	5.89%	11.53%	11.34%	15.36%	12.55%	11.69%	12.03%	12.42%
Tax Burden Percent	61.22%	61.42%	83.97%	85.79%	84.07%	80.68%	76.66%	75.72%	77.78%	75.60%
Interest Burden Percent	98.02%	97.94%	96.47%	97.96%	98.30%	99.41%	99.47%	98.63%	99.12%	99.56%
Effective Tax Rate	38.78%	38.58%	16.03%	14.21%	15.93%	19.32%	23.34%	24.28%	22.22%	24.40%
Return on Invested Capital (ROIC)	19.23%	18.19%	15.21%	32.00%	29.12%	40.59%	34.74%	32.56%	31.80%	31.05%
ROIC Less NNEP Spread (ROIC-NNEP)	16.70%	16.96%	18.76%	28.04%	33.34%	27.68%	-70.80%	20.64%	25.46%	19.78%
Return on Net Nonoperating Assets (RNNOA)	3.63%	2.78%	3.24%	4.32%	4.26%	-1.34%	0.49%	2.55%	-3.21%	-3.93%
Return on Equity (ROE)	22.86%	20.97%	18.45%	36.33%	33.37%	39.25%	35.23%	35.11%	28.59%	27.12%
Cash Return on Invested Capital (CROIC)	18.37%	13.59%	13.15%	25.07%	10.98%	49.88%	29.87%	26.71%	29.18%	20.21%
Operating Return on Assets (OROA)	21.47%	20.87%	13.46%	25.81%	23.72%	29.47%	25.36%	24.01%	22.73%	24.05%
Return on Assets (ROA)	12.88%	12.55%	10.91%	21.69%	19.60%	23.64%	19.34%	17.93%	17.52%	18.10%
Return on Common Equity (ROCE)	22.86%	20.97%	18.45%	36.33%	33.37%	39.25%	35.23%	35.11%	28.59%	27.12%
Return on Equity Simple (ROE_SIMPLE)	21.49%	20.75%	18.17%	34.76%	30.27%	35.45%	43.09%	31.25%	24.60%	26.99%
Net Operating Profit after Tax (NOPAT)	113	110	95	209	216	314	263	260	265	277
NOPAT Margin	7.32%	6.96%	5.69%	11.72%	11.16%	15.12%	12.29%	12.18%	11.70%	11.40%
Net Nonoperating Expense Percent (NNEP)	2.53%	1.23%	-3.55%	3.97%	-4.23%	12.91%	105.54%	11.92%	6.34%	11.27%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	29.02%	23.91%	24.76%
Cost of Revenue to Revenue	70.47%	70.74%	69.03%	68.87%	68.15%	66.27%	64.02%	64.16%	64.72%	64.86%
SG&A Expenses to Revenue	15.41%	15.73%	16.60%	15.21%	15.77%	15.88%	17.14%	16.80%	17.45%	17.45%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	17.58%	17.93%	24.19%	17.47%	18.57%	14.99%	19.95%	19.75%	20.24%	20.07%
Earnings before Interest and Taxes (EBIT)	184	181	121	245	266	398	352	334	353	401
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	220	218	159	284	312	455	412	394	415	465
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.76	4.83	7.02	7.53	9.54	9.32	12.95	9.44	7.92	7.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	441.28	356.06	302.97	41.04	0.00	64.04	20.28	22.03
Price to Revenue (P/Rev)	1.58	1.61	2.28	2.50	3.57	4.04	3.77	3.53	3.87	3.26
Price to Earnings (P/E)	22.14	23.29	38.66	21.67	31.51	26.28	30.06	30.19	32.19	26.26
Dividend Yield	0.64%	0.64%	0.45%	0.42%	0.29%	0.25%	0.27%	0.37%	0.27%	0.34%
Earnings Yield	4.52%	4.29%	2.59%	4.61%	3.17%	3.81%	3.33%	3.31%	3.11%	3.81%
Enterprise Value to Invested Capital (EV/IC)	4.27	4.25	6.16	6.72	8.65	11.15	10.61	9.20	10.08	8.24
Enterprise Value to Revenue (EV/Rev)	1.63	1.67	2.33	2.55	3.62	3.96	3.84	3.54	3.76	3.19
Enterprise Value to EBITDA (EV/EBITDA)	11.45	12.06	24.51	15.96	22.50	18.08	19.98	19.20	20.50	16.69
Enterprise Value to EBIT (EV/EBIT)	13.70	14.53	32.07	18.56	26.35	20.67	23.35	22.62	24.07	19.32
Enterprise Value to NOPAT (EV/NOPAT)	22.30	23.92	40.94	21.72	32.41	26.19	31.27	29.07	32.12	27.98
Enterprise Value to Operating Cash Flow (EV/OCF)	14.69	19.39	23.91	15.81	23.28	16.82	26.65	24.40	25.76	18.57
Enterprise Value to Free Cash Flow (EV/FCFF)	23.35	32.01	47.38	27.72	85.92	21.31	36.37	35.43	35.00	42.98
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.18	0.21	0.19	0.15	0.12	0.00	0.30	0.12	0.00	0.00
Long-Term Debt to Equity	0.16	0.19	0.17	0.15	0.12	0.00	0.30	0.12	0.00	0.00
Financial Leverage	0.22	0.16	0.17	0.15	0.13	-0.05	-0.01	0.12	-0.13	-0.20
Leverage Ratio	1.78	1.67	1.69	1.68	1.70	1.66	1.82	1.96	1.63	1.50
Compound Leverage Factor	1.74	1.64	1.63	1.64	1.67	1.65	1.81	1.93	1.62	1.49
Debt to Total Capital	15.10%	17.18%	15.77%	13.11%	11.02%	0.00%	22.89%	10.88%	0.00%	0.00%
Short-Term Debt to Total Capital	1.24%	1.38%	1.56%	0.00%	0.00%	0.00%	0.00%	0.56%	0.00%	0.00%
Long-Term Debt to Total Capital	13.85%	15.80%	14.22%	13.11%	11.02%	0.00%	22.89%	10.32%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.91%	82.82%	84.23%	86.89%	88.98%	100.00%	77.11%	89.12%	100.00%	100.00%
Debt to EBITDA	0.42	0.50	0.64	0.31	0.29	0.00	0.45	0.25	0.00	0.00
Net Debt to EBITDA	0.35	0.43	0.57	0.30	0.27	0.00	0.37	0.06	0.00	0.00
Long-Term Debt to EBITDA	0.38	0.46	0.58	0.31	0.29	0.00	0.45	0.23	0.00	0.00
Debt to NOPAT	0.81	0.99	1.07	0.43	0.42	0.00	0.70	0.37	0.00	0.00
Net Debt to NOPAT	0.68	0.85	0.95	0.40	0.39	0.00	0.58	0.09	0.00	0.00
Long-Term Debt to NOPAT	0.74	0.91	0.96	0.43	0.42	0.00	0.70	0.36	0.00	0.00
Altman Z-Score	8.24	8.26	9.80	11.33	11.40	13.51	11.18	11.39	13.64	13.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.88	0.99	0.91	0.83	0.73	1.10	0.76	0.92	1.61	1.38
Quick Ratio	0.71	0.86	0.64	0.65	0.57	0.97	0.56	0.72	1.43	1.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	108	82	82	164	82	386	226	213	243	180
Operating Cash Flow to CapEx	388.58%	340.42%	252.71%	543.08%	568.16%	856.33%	534.17%	563.48%	587.57%	903.36%
Free Cash Flow to Firm to Interest Expense	29.60	22.08	19.20	32.81	18.00	164.03	121.05	46.55	78.20	101.32
Operating Cash Flow to Interest Expense	47.05	36.45	38.04	57.54	66.43	207.77	165.20	67.60	106.27	234.55
Operating Cash Flow Less CapEx to Interest Expense	34.94	25.74	22.99	46.95	54.74	183.50	134.28	55.60	88.19	208.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.80	1.82	1.85	1.88	1.73	1.54	1.54	1.53	1.46	1.46
Accounts Receivable Turnover	13.37	13.24	13.57	15.29	14.72	15.37	16.20	15.44	14.11	13.79
Inventory Turnover	174.27	184.84	207.51	222.42	200.67	189.35	159.20	134.43	131.59	156.16
Fixed Asset Turnover	13.86	13.21	12.61	11.69	11.48	11.44	11.22	10.85	11.22	12.02
Accounts Payable Turnover	24.02	26.79	26.16	24.92	26.10	26.17	21.52	23.84	27.67	29.15
Days Sales Outstanding (DSO)	27.30	27.58	26.90	23.87	24.79	23.75	22.53	23.65	25.86	26.47
Days Inventory Outstanding (DIO)	2.09	1.97	1.76	1.64	1.82	1.93	2.29	2.72	2.77	2.34
Days Payable Outstanding (DPO)	15.19	13.63	13.95	14.65	13.99	13.95	16.96	15.31	13.19	12.52
Cash Conversion Cycle (CCC)	14.20	15.93	14.71	10.86	12.62	11.73	7.86	11.05	15.45	16.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	590	618	630	676	810	739	775	822	844	941
Invested Capital Turnover	2.63	2.61	2.67	2.73	2.61	2.69	2.83	2.67	2.72	2.72
Increase / (Decrease) in Invested Capital	5.05	28	13	45	135	-72	37	47	22	97
Enterprise Value (EV)	2,518	2,626	3,886	4,539	7,013	8,232	8,223	7,561	8,508	7,752
Market Capitalization	2,442	2,532	3,796	4,455	6,929	8,395	8,071	7,537	8,772	7,931
Book Value per Share	$30.41	$32.30	$33.84	$36.93	$45.39	$56.50	$40.49	$53.71	$73.55	$74.69
Tangible Book Value per Share	($0.84)	($0.21)	$0.54	$0.78	$1.43	$12.82	($4.12)	$7.91	$28.72	$24.03
Total Capital	605	633	642	681	817	901	808	896	1,108	1,119
Total Debt	91	109	101	89	90	0.00	185	98	0.00	0.00
Total Long-Term Debt	84	100	91	89	90	0.00	185	93	0.00	0.00
Net Debt	77	93	90	84	84	-163	152	23	-264	-178
Capital Expenditures (CapEx)	44	40	64	53	53	57	58	55	56	46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-8.49	-19	-37	-78	-132	-105	-94	-75	-69
Debt-free Net Working Capital (DFNWC)	-13	6.82	-7.48	-32	-72	30	-72	-20	189	109
Net Working Capital (NWC)	-21	-1.93	-17	-32	-72	30	-72	-25	189	109
Net Nonoperating Expense (NNE)	2.65	1.04	-3.26	3.46	-3.56	-5.09	-5.58	10	-7.62	-25
Net Nonoperating Obligations (NNO)	77	93	90	84	84	-163	152	23	-264	-178
Total Depreciation and Amortization (D&A)	36	37	37	40	46	57	59	60	61	63
Debt-free, Cash-free Net Working Capital to Revenue	-1.80%	-0.54%	-1.12%	-2.06%	-4.01%	-6.37%	-4.91%	-4.39%	-3.32%	-2.85%
Debt-free Net Working Capital to Revenue	-0.84%	0.43%	-0.45%	-1.79%	-3.69%	1.46%	-3.37%	-0.92%	8.34%	4.49%
Net Working Capital to Revenue	-1.33%	-0.12%	-1.05%	-1.79%	-3.69%	1.46%	-3.37%	-1.15%	8.34%	4.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$6.54	$6.64	$6.11	$12.80	$13.77	$20.02	$17.14	$16.72	$18.11	$20.10
Adjusted Weighted Average Basic Shares Outstanding	16.87M	16.38M	16.06M	16.06M	15.97M	15.96M	15.67M	14.93M	15.05M	15.02M
Adjusted Diluted Earnings per Share	$6.33	$6.48	$5.86	$12.23	$13.31	$19.48	$16.85	$16.53	$17.93	$19.89
Adjusted Weighted Average Diluted Shares Outstanding	17.42M	16.79M	16.74M	16.80M	16.53M	16.40M	15.94M	15.10M	15.20M	15.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	16.99M	16.31M	16.16M	15.97M	16.06M	16.03M	14.99M	14.95M	15.12M	14.64M
Normalized Net Operating Profit after Tax (NOPAT)	113	110	95	209	216	314	263	260	265	277
Normalized NOPAT Margin	7.32%	6.96%	5.69%	11.72%	11.16%	15.12%	12.29%	12.18%	11.70%	11.40%
Pre Tax Income Margin	11.67%	11.23%	7.01%	13.44%	13.50%	19.04%	16.38%	15.44%	15.47%	16.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	50.42	48.66	28.37	49.02	58.69	169.15	188.53	72.92	113.73	225.42
NOPAT to Interest Expense	30.98	29.55	22.22	41.88	47.71	133.49	140.78	56.74	85.23	155.66
EBIT Less CapEx to Interest Expense	38.31	37.95	13.32	38.42	46.99	144.89	157.61	60.92	95.64	199.45
NOPAT Less CapEx to Interest Expense	18.87	18.85	7.17	31.29	36.02	109.23	109.85	44.74	67.14	129.69
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	14.15%	15.12%	17.69%	9.08%	9.00%	6.60%	8.20%	8.82%	8.62%	8.97%
Augmented Payout Ratio	82.22%	117.27%	114.09%	86.38%	51.12%	61.56%	222.70%	54.70%	33.47%	128.64%

This table displays calculated financial ratios and metrics derived from Chemed's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.26%	1.05%	5.58%	4.24%	7.23%	7.18%	5.19%	7.60%	7.38%	9.23%
EBITDA Growth	-16.23%	-11.14%	-12.60%	-15.37%	18.01%	33.28%	15.05%	27.10%	7.39%	3.78%
EBIT Growth	-19.02%	-13.09%	-14.96%	-18.27%	20.54%	38.02%	16.77%	32.54%	8.27%	4.04%
NOPAT Growth	-14.19%	-19.43%	-18.21%	-25.67%	16.08%	41.53%	0.52%	26.24%	-0.98%	-1.33%
Net Income Growth	-21.01%	-16.75%	-15.66%	-19.68%	31.80%	44.95%	20.13%	32.80%	1.09%	0.30%
EPS Growth	-16.92%	-13.60%	-15.17%	-20.23%	30.42%	43.10%	18.44%	32.48%	1.42%	1.52%
Operating Cash Flow Growth	-53.96%	57.62%	-40.16%	133.86%	-44.39%	8.35%	39.77%	-41.42%	212.92%	51.91%
Free Cash Flow Firm Growth	-143.56%	-62.79%	-208.01%	-8.32%	1,232.00%	344.70%	248.87%	-338.42%	-314.93%	-117.09%
Invested Capital Growth	8.46%	6.02%	9.72%	0.00%	3.88%	2.66%	3.19%	24.27%	17.87%	11.46%
Revenue Q/Q Growth	-0.91%	3.83%	2.47%	-1.13%	1.93%	3.79%	0.57%	1.13%	1.73%	5.58%
EBITDA Q/Q Growth	-9.59%	6.70%	-11.24%	-1.17%	26.08%	20.51%	-23.38%	9.18%	6.53%	16.46%
EBIT Q/Q Growth	-10.65%	8.05%	-13.43%	-2.20%	31.77%	23.72%	-26.76%	11.01%	7.64%	18.89%
NOPAT Q/Q Growth	-15.25%	1.97%	-9.68%	-4.76%	32.35%	24.33%	-35.86%	19.61%	3.82%	23.87%
Net Income Q/Q Growth	-14.42%	9.24%	-12.89%	-1.37%	40.43%	20.14%	-27.80%	9.03%	6.90%	19.19%
EPS Q/Q Growth	-14.09%	9.26%	-13.32%	-1.96%	40.46%	19.88%	-28.26%	9.67%	7.53%	20.00%
Operating Cash Flow Q/Q Growth	-8.06%	92.63%	-39.63%	118.73%	-78.14%	275.30%	-22.12%	-8.32%	16.77%	82.19%
Free Cash Flow Firm Q/Q Growth	-105.87%	532.89%	-232.31%	372.73%	-27.53%	70.06%	-55.71%	-536.79%	34.67%	86.48%
Invested Capital Q/Q Growth	2.82%	0.93%	2.57%	-6.06%	6.81%	-0.26%	3.11%	13.13%	1.31%	-5.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	34.10%	36.05%	33.82%	32.43%	35.81%	38.84%	34.64%	34.59%	34.64%	36.58%
EBITDA Margin	17.57%	18.06%	15.64%	15.63%	19.34%	22.45%	17.11%	18.47%	19.34%	21.33%
Operating Margin	15.36%	14.88%	13.00%	12.55%	15.38%	19.01%	12.28%	14.79%	15.20%	17.79%
EBIT Margin	14.77%	15.37%	12.98%	12.84%	16.60%	19.79%	14.41%	15.82%	16.74%	18.85%
Profit (Net Income) Margin	10.80%	11.36%	9.66%	9.64%	13.28%	15.37%	11.03%	11.90%	12.50%	14.11%
Tax Burden Percent	74.37%	75.40%	76.05%	75.88%	80.37%	77.91%	76.96%	75.55%	75.00%	75.19%
Interest Burden Percent	98.37%	98.09%	97.87%	98.92%	99.53%	99.71%	99.50%	99.54%	99.58%	99.59%
Effective Tax Rate	25.63%	24.60%	23.95%	24.12%	19.63%	22.09%	23.04%	24.45%	25.00%	24.81%
Return on Invested Capital (ROIC)	31.07%	29.98%	26.55%	26.29%	33.14%	40.26%	25.29%	29.38%	29.41%	36.45%
ROIC Less NNEP Spread (ROIC-NNEP)	20.93%	30.90%	22.69%	23.88%	20.26%	37.54%	19.95%	27.13%	26.18%	34.33%
Return on Net Nonoperating Assets (RNNOA)	0.90%	3.81%	0.95%	-0.77%	-0.93%	-4.74%	-3.39%	-4.81%	-4.78%	-6.82%
Return on Equity (ROE)	31.97%	33.80%	27.51%	25.52%	32.20%	35.53%	21.91%	24.57%	24.63%	29.64%
Cash Return on Invested Capital (CROIC)	27.01%	26.71%	21.47%	28.98%	25.03%	29.18%	27.79%	9.74%	13.77%	20.21%
Operating Return on Assets (OROA)	23.51%	23.56%	20.53%	19.93%	25.31%	28.81%	20.93%	22.80%	23.89%	27.47%
Return on Assets (ROA)	17.20%	17.43%	15.28%	14.96%	20.25%	22.38%	16.02%	17.15%	17.84%	20.57%
Return on Common Equity (ROCE)	31.97%	33.80%	27.51%	25.52%	32.20%	35.53%	21.91%	24.57%	24.63%	29.64%
Return on Equity Simple (ROE_SIMPLE)	36.33%	0.00%	27.22%	23.79%	24.00%	0.00%	23.95%	24.92%	24.42%	0.00%
Net Operating Profit after Tax (NOPAT)	60	61	55	53	70	87	56	67	69	86
NOPAT Margin	11.42%	11.22%	9.89%	9.52%	12.36%	14.81%	9.45%	11.17%	11.40%	13.38%
Net Nonoperating Expense Percent (NNEP)	10.14%	-0.92%	3.87%	2.41%	12.88%	2.72%	5.34%	2.25%	3.23%	2.12%
Return On Investment Capital (ROIC_SIMPLE)	-	6.84%	-	-	-	7.83%	-	-	-	7.65%
Cost of Revenue to Revenue	65.90%	63.95%	66.18%	67.57%	64.19%	61.16%	65.36%	65.41%	65.36%	63.42%
SG&A Expenses to Revenue	15.95%	17.73%	17.87%	17.15%	17.64%	17.14%	19.67%	17.16%	16.82%	16.29%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	18.74%	21.18%	20.82%	19.88%	20.43%	19.83%	22.36%	19.80%	19.44%	18.79%
Earnings before Interest and Taxes (EBIT)	78	84	73	71	94	116	85	94	101	121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	93	99	88	87	109	132	101	110	117	137
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.96	9.44	9.09	8.51	7.66	7.92	8.19	6.80	7.32	7.09
Price to Tangible Book Value (P/TBV)	163.93	64.04	39.73	29.41	22.88	20.28	19.23	18.31	19.08	22.03
Price to Revenue (P/Rev)	3.04	3.53	3.70	3.71	3.51	3.87	4.22	3.51	3.80	3.26
Price to Earnings (P/E)	24.66	30.19	33.40	35.79	31.94	32.19	34.19	27.27	29.98	26.26
Dividend Yield	0.34%	0.37%	0.35%	0.35%	0.37%	0.27%	0.25%	0.30%	0.28%	0.34%
Earnings Yield	4.06%	3.31%	2.99%	2.79%	3.13%	3.11%	2.93%	3.67%	3.34%	3.81%
Enterprise Value to Invested Capital (EV/IC)	8.05	9.20	9.45	10.03	9.03	10.08	10.77	8.11	8.83	8.24
Enterprise Value to Revenue (EV/Rev)	3.08	3.54	3.68	3.63	3.43	3.76	4.09	3.42	3.70	3.19
Enterprise Value to EBITDA (EV/EBITDA)	16.14	19.20	20.90	21.74	19.99	20.50	21.90	17.68	19.16	16.69
Enterprise Value to EBIT (EV/EBIT)	18.90	22.62	24.78	26.00	23.76	24.07	25.64	20.54	22.21	19.32
Enterprise Value to NOPAT (EV/NOPAT)	23.85	29.07	32.15	34.60	31.90	32.12	35.38	28.64	31.67	27.98
Enterprise Value to Operating Cash Flow (EV/OCF)	23.99	24.40	29.58	23.03	23.73	25.76	26.46	26.65	24.38	18.57
Enterprise Value to Free Cash Flow (EV/FCFF)	31.01	35.43	46.03	34.61	36.76	35.00	39.37	92.25	69.40	42.98
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.12	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.13	0.12	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.04	0.12	0.04	-0.03	-0.05	-0.13	-0.17	-0.18	-0.18	-0.20
Leverage Ratio	1.78	1.96	1.77	1.72	1.68	1.63	1.53	1.50	1.48	1.50
Compound Leverage Factor	1.75	1.92	1.73	1.70	1.67	1.63	1.52	1.49	1.47	1.49
Debt to Total Capital	12.26%	10.88%	2.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.61%	0.56%	0.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	11.66%	10.32%	1.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.74%	89.12%	97.64%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.25	0.25	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.23	0.06	-0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.24	0.23	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.37	0.37	0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.34	0.09	-0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.35	0.36	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.99	10.82	12.57	12.56	12.45	13.17	14.38	13.07	13.94	12.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.67	0.92	0.93	1.11	1.33	1.61	1.91	1.78	1.85	1.38
Quick Ratio	0.43	0.72	0.75	0.93	1.15	1.43	1.74	1.56	1.64	1.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.37	15	-19	53	38	65	29	-126	-82	-11
Operating Cash Flow to CapEx	394.79%	557.71%	358.49%	817.48%	251.34%	932.27%	700.08%	941.65%	675.46%	1,318.67%
Free Cash Flow to Firm to Interest Expense	-2.65	9.12	-12.46	68.36	86.02	189.92	67.69	-292.92	-192.25	-22.25
Operating Cash Flow to Interest Expense	40.93	62.59	39.00	171.62	65.15	317.44	198.94	180.69	211.99	330.49
Operating Cash Flow Less CapEx to Interest Expense	30.56	51.36	28.12	150.62	39.23	283.39	170.52	161.50	180.60	305.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.59	1.53	1.58	1.55	1.53	1.46	1.45	1.44	1.43	1.46
Accounts Receivable Turnover	17.75	15.44	15.97	17.03	15.36	14.11	13.85	15.30	13.04	13.79
Inventory Turnover	143.84	134.43	132.44	128.81	126.79	131.59	138.48	133.42	136.49	156.16
Fixed Asset Turnover	11.08	10.85	10.92	10.93	11.15	11.22	11.27	11.38	11.70	12.02
Accounts Payable Turnover	19.77	23.84	26.75	25.06	21.80	27.67	30.68	35.58	30.15	29.15
Days Sales Outstanding (DSO)	20.56	23.65	22.86	21.43	23.76	25.86	26.35	23.85	27.98	26.47
Days Inventory Outstanding (DIO)	2.54	2.72	2.76	2.83	2.88	2.77	2.64	2.74	2.67	2.34
Days Payable Outstanding (DPO)	18.46	15.31	13.65	14.56	16.75	13.19	11.90	10.26	12.11	12.52
Cash Conversion Cycle (CCC)	4.64	11.05	11.97	9.70	9.89	15.45	17.09	16.33	18.55	16.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	814	822	843	792	846	844	870	984	997	941
Invested Capital Turnover	2.72	2.67	2.69	2.76	2.68	2.72	2.68	2.63	2.58	2.72
Increase / (Decrease) in Invested Capital	64	47	75	0.04	32	22	27	192	151	97
Enterprise Value (EV)	6,556	7,561	7,966	7,945	7,639	8,508	9,375	7,984	8,806	7,752
Market Capitalization	6,463	7,537	8,003	8,105	7,812	8,772	9,689	8,207	9,045	7,931
Book Value per Share	$48.40	$53.71	$58.87	$63.39	$67.60	$73.55	$78.29	$79.75	$82.11	$74.69
Tangible Book Value per Share	$2.65	$7.91	$13.47	$18.35	$22.65	$28.72	$33.33	$29.60	$31.50	$24.03
Total Capital	822	896	901	952	1,019	1,108	1,183	1,207	1,236	1,119
Total Debt	101	98	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	96	93	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	93	23	-37	-160	-173	-264	-313	-223	-238	-178
Capital Expenditures (CapEx)	13	18	17	16	12	12	12	8.23	13	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-102	-94	-74	-125	-76	-75	-56	-20	-13	-69
Debt-free Net Working Capital (DFNWC)	-94	-20	-16	35	97	189	258	203	226	109
Net Working Capital (NWC)	-99	-25	-21	35	97	189	258	203	226	109
Net Nonoperating Expense (NNE)	3.26	-0.81	1.26	-0.64	-5.16	-3.27	-9.35	-4.31	-6.65	-4.70
Net Nonoperating Obligations (NNO)	93	23	-37	-160	-173	-264	-313	-223	-238	-178
Total Depreciation and Amortization (D&A)	15	15	15	15	15	16	16	16	16	16
Debt-free, Cash-free Net Working Capital to Revenue	-4.79%	-4.39%	-3.43%	-5.73%	-3.41%	-3.32%	-2.43%	-0.86%	-0.54%	-2.85%
Debt-free Net Working Capital to Revenue	-4.43%	-0.92%	-0.75%	1.59%	4.37%	8.34%	11.23%	8.69%	9.49%	4.49%
Net Working Capital to Revenue	-4.66%	-1.15%	-0.98%	1.59%	4.37%	8.34%	11.23%	8.69%	9.49%	4.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.82	$4.17	$3.62	$3.54	$4.97	$5.98	$4.30	$4.70	$5.04	$6.06
Adjusted Weighted Average Basic Shares Outstanding	14.89M	14.93M	14.97M	15.06M	15.08M	15.05M	15.12M	15.10M	15.03M	15.02M
Adjusted Diluted Earnings per Share	$3.78	$4.13	$3.58	$3.51	$4.93	$5.91	$4.24	$4.65	$5.00	$6.00
Adjusted Weighted Average Diluted Shares Outstanding	15.04M	15.10M	15.11M	15.22M	15.20M	15.20M	15.34M	15.25M	15.17M	15.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.87M	14.95M	15.02M	15.08M	15.06M	15.12M	15.14M	15.05M	14.98M	14.64M
Normalized Net Operating Profit after Tax (NOPAT)	60	61	55	53	70	87	56	67	69	86
Normalized NOPAT Margin	11.42%	11.22%	9.89%	9.52%	12.36%	14.81%	9.45%	11.17%	11.40%	13.38%
Pre Tax Income Margin	14.53%	15.07%	12.70%	12.70%	16.52%	19.73%	14.34%	15.75%	16.67%	18.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	61.17	52.47	46.88	92.24	211.06	338.99	199.79	219.71	237.60	241.73
NOPAT to Interest Expense	47.31	38.30	35.71	68.41	157.21	253.75	130.98	155.19	161.88	171.59
EBIT Less CapEx to Interest Expense	50.80	41.25	36.00	71.24	185.14	304.94	171.37	200.52	206.22	216.67
NOPAT Less CapEx to Interest Expense	36.95	27.08	24.83	47.41	131.29	219.70	102.56	136.01	130.49	146.53
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	8.37%	8.82%	9.34%	10.03%	9.43%	8.62%	8.42%	8.04%	8.50%	8.97%
Augmented Payout Ratio	140.83%	54.70%	45.54%	32.42%	26.09%	33.47%	45.88%	57.39%	72.13%	128.64%

Frequently Asked Questions About Chemed's Financials

When does Chemed's fiscal year end?

According to the most recent income statement we have on file, Chemed's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Chemed's net income changed over the last 9 years?

Chemed's net income appears to be on an upward trend, with a most recent value of $302.00 million in 2024, rising from $110.27 million in 2015. The previous period was $272.51 million in 2023.

What is Chemed's operating income?

Chemed's total operating income in 2024 was $366.49 million, based on the following breakdown:

Total Gross Profit: $854.35 million
Total Operating Expenses: $487.86 million

How has Chemed revenue changed over the last 9 years?

Over the last 9 years, Chemed's total revenue changed from $1.54 billion in 2015 to $2.43 billion in 2024, a change of 57.5%.

How much debt does Chemed have?

Chemed's total liabilities were at $549.58 million at the end of 2024, a 1.9% decrease from 2023, and a 62.1% increase since 2015.

How much cash does Chemed have?

In the past 9 years, Chemed's cash and equivalents has ranged from $4.83 million in 2018 to $263.96 million in 2023, and is currently $178.35 million as of their latest financial filing in 2024.

How has Chemed's book value per share changed over the last 9 years?

Over the last 9 years, Chemed's book value per share changed from 30.41 in 2015 to 74.69 in 2024, a change of 145.6%.

Related Companies

This page (NYSE:CHE) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Financials

Frequently Asked Questions About Chemed's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemed (CHE) Financials

Annual Income Statements for Chemed

Quarterly Income Statements for Chemed

Annual Cash Flow Statements for Chemed

Quarterly Cash Flow Statements for Chemed

Annual Balance Sheets for Chemed

Quarterly Balance Sheets for Chemed

Annual Metrics and Ratios for Chemed

Quarterly Metrics and Ratios for Chemed

Frequently Asked Questions About Chemed's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools